Christina Trojel-Hansen

Christina Trojel-Hansen PhD has an extensive work experience in the medical field. Christina began their career in 2016 as a Board Observer for Macrophage Pharma Ltd. In 2017, they became the Co-Founder and CEO of Oscine Therapeutics, a cell therapy company for intractable CNS and myelin diseases. In 2018, they joined ARCH Venture Partners as an EIR, and also became an Adjunct Assistant Professor at the University of Rochester Medical Center. In 2019, they became an Entrepreneur In Residence and a member of the Therapeutics Advisory Group at the BioInnovation Institute. Christina also co-founded Pretzel Therapeutics and Trojel Inc. in 2019 and 2020 respectively. In 2020, they co-founded Tune Therapeutics, and in 2021 they co-founded CNS2 and Comorin.

Christina Trojel-Hansen PhD began their education in 2003 at Interdisciplinary Nanoscience Center (iNANO) in Aarhus, Denmark, where they earned their MSc in Nanotechnology/Nanobiotechnology/Advanced Materials in 2008. Christina then pursued a Industrial PhD at the University of Copenhagen and University of California Berkeley, which they completed in 2011. In 2015 and 2016, they attended Denmark Technical University Executive School of Business and earned a Certificate in Entrepreneurial Leadership (CEL).